Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

64
Oncolix, Inc. Forms Scientific and Clinical Advisory Board and Appoints First Member

19h accesswire
HOUSTON, TX / ACCESSWIRE / July 17, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has appointed Robert Niecestro, PhD as its first member of its Regulatory Strategy, Scientific and Clinical Advisory Board.
ATXI AXSM TGTX KERX CKPT CTXR

65
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-07-11 sec.gov
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease July 11, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 000-30929 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.
KERX

58
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?

2018-07-06 seekingalpha
The merger offers up to 250M in potential cost savings, and combined kidney disease expertise all under one roof.
KERX AKBA

62
More than $100 Billion Spent on M&A in the First 6 Months of 2018

2018-07-06 biospace
For many biotech companies, mergers and acquisitions have become a cornerstone in building a robust pipeline that can ensure positive growth for years to come. Although 2017 was slow for M&A activity, analysts have predicted 2018 could be a return to a spending frenzy.
JUNO CASC KERX AKBA

70
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

2018-07-05 zacks
It’s been a pretty low-key week for the biotech sector, with not too many major updates. Among the key news, Gilead’s (GILD - Free Report) CAR-T therapy won CHMP positive opinion, while Keryx Biopharmaceuticals (KERX - Free Report) plunged on merger news.
XLRN AMGN CELGZ CELG CARA KERX AKBA

68
KERX / Keryx Biopharmaceuticals, Inc. FORM 8-K (Current Report)

2018-07-03 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
KERX

16
KERX / Keryx Biopharmaceuticals, Inc. S-8

2018-06-29 sec.gov
S-8 As filed with the Securities and Exchange Commission on June 29, 2018 REGISTRATION NO. 333 -
KERX

42
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

2018-06-29 zacks
Shares of Keryx Biopharmaceuticals, Inc. (KERX - Free Report) went down by about 19% as the company signed a definitive merger agreement with Akebia Therapeutics, Inc. (AKBA - Free Report) , under which the companies will combine in an all-stock merger. The companies are to form a new, fully integrated company focused on chronic kidney diseases (or CKD) called Akebia Therapeutics. The deal is expected to close by the end of 2018, unless any concerns are raised by antitrust authorities or shareholders.
ANIP AGLE KERX PII AKBA

239
4 Biotech Stocks to Bet on in the Second Half of 2018

2018-06-29 zacks
It has been a pretty ho-hum first-half of 2018 for the biotech sector. The NASDAQ Biotechnology Index (^NBI) has lost 1.2% so far in 2018.
CLSN ATHX VRTX AMGN GILD JUNO AGLE CELG KERX PII AKBA

27
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call - Transcript

2018-06-29 seekingalpha
Good day ladies and gentlemen, and welcome to the Akebia Therapeutics and Keryx Biopharmaceuticals Joint Corporate Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call may be recorded. I would now like to turn the conference over to Amy Sullivan, Senior Vice President, Corporate Affairs. You may begin.
KERX AKBA

13
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-06-28 sec.gov
425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934
KERX

13
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-06-28 sec.gov
425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934
KERX

14
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-06-28 sec.gov
425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934
KERX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to KERX / Keryx Biopharmaceuticals, Inc. on message board site Silicon Investor.

Keryx Biopharmaceuticals Inc (KERX)
CUSIP: 492515101